Aurora Cannabis (ACB) Competitors $5.42 -0.05 (-0.90%) As of 09:40 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ACB vs. ETNB, AUPH, GYRE, MLYS, WVE, PAHC, ARDX, COLL, NTLA, and RCUSShould you be buying Aurora Cannabis stock or one of its competitors? The main competitors of Aurora Cannabis include 89bio (ETNB), Aurinia Pharmaceuticals (AUPH), Gyre Therapeutics (GYRE), Mineralys Therapeutics (MLYS), Wave Life Sciences (WVE), Phibro Animal Health (PAHC), Ardelyx (ARDX), Collegium Pharmaceutical (COLL), Intellia Therapeutics (NTLA), and Arcus Biosciences (RCUS). These companies are all part of the "pharmaceutical products" industry. Aurora Cannabis vs. 89bio Aurinia Pharmaceuticals Gyre Therapeutics Mineralys Therapeutics Wave Life Sciences Phibro Animal Health Ardelyx Collegium Pharmaceutical Intellia Therapeutics Arcus Biosciences 89bio (NASDAQ:ETNB) and Aurora Cannabis (NASDAQ:ACB) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, community ranking, media sentiment, risk, profitability, earnings and institutional ownership. Is ETNB or ACB more profitable? Aurora Cannabis has a net margin of 0.42% compared to 89bio's net margin of 0.00%. Aurora Cannabis' return on equity of 0.59% beat 89bio's return on equity.Company Net Margins Return on Equity Return on Assets 89bioN/A -59.58% -52.21% Aurora Cannabis 0.42%0.59%0.42% Do analysts rate ETNB or ACB? 89bio currently has a consensus target price of $26.43, suggesting a potential upside of 188.52%. Given 89bio's higher possible upside, research analysts clearly believe 89bio is more favorable than Aurora Cannabis.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score 89bio 0 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 2 Strong Buy rating(s) 3.00Aurora Cannabis 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 2 Strong Buy rating(s) 3.67 Does the media refer more to ETNB or ACB? In the previous week, 89bio had 5 more articles in the media than Aurora Cannabis. MarketBeat recorded 8 mentions for 89bio and 3 mentions for Aurora Cannabis. Aurora Cannabis' average media sentiment score of 1.35 beat 89bio's score of 0.93 indicating that Aurora Cannabis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment 89bio 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aurora Cannabis 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has higher earnings and valuation, ETNB or ACB? Aurora Cannabis has higher revenue and earnings than 89bio. 89bio is trading at a lower price-to-earnings ratio than Aurora Cannabis, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio89bioN/AN/A-$142.19M-$3.38-2.71Aurora Cannabis$320.81M0.96-$48.62M$0.05109.40 Does the MarketBeat Community believe in ETNB or ACB? Aurora Cannabis received 269 more outperform votes than 89bio when rated by MarketBeat users. However, 61.83% of users gave 89bio an outperform vote while only 59.63% of users gave Aurora Cannabis an outperform vote. CompanyUnderperformOutperform89bioOutperform Votes11561.83% Underperform Votes7138.17% Aurora CannabisOutperform Votes38459.63% Underperform Votes26040.37% Which has more risk & volatility, ETNB or ACB? 89bio has a beta of 1.23, meaning that its stock price is 23% more volatile than the S&P 500. Comparatively, Aurora Cannabis has a beta of 1.94, meaning that its stock price is 94% more volatile than the S&P 500. Do insiders and institutionals hold more shares of ETNB or ACB? 47.6% of Aurora Cannabis shares are held by institutional investors. 2.6% of 89bio shares are held by company insiders. Comparatively, 0.0% of Aurora Cannabis shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. SummaryAurora Cannabis beats 89bio on 12 of the 17 factors compared between the two stocks. Get Aurora Cannabis News Delivered to You Automatically Sign up to receive the latest news and ratings for ACB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ACB vs. The Competition Export to ExcelMetricAurora CannabisMedicinals & botanicals IndustryMedical SectorNASDAQ ExchangeMarket Cap$307.49M$1.20B$5.38B$8.46BDividend YieldN/AN/A5.28%4.17%P/E Ratio109.4211.2827.0319.89Price / Sales0.9610.03403.36138.33Price / Cash26.3510.4038.2534.64Price / Book0.671.476.774.56Net Income-$48.62M-$54.34M$3.22B$248.06M7 Day Performance4.79%-0.23%1.71%2.14%1 Month Performance16.88%1.72%6.97%9.07%1 Year Performance-13.31%-37.00%19.51%9.74% Aurora Cannabis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ACBAurora Cannabis0.7134 of 5 stars$5.42-0.9%N/A-17.9%$305.52M$320.81M108.721,340Positive NewsGap UpETNB89bio2.579 of 5 stars$7.70-1.0%$26.43+243.2%+12.5%$1.12BN/A-2.6540News CoverageAUPHAurinia Pharmaceuticals3.0609 of 5 stars$8.07-1.5%$11.50+42.5%+56.4%$1.09B$247.30M-53.80300Positive NewsGYREGyre Therapeutics0.3025 of 5 stars$11.11-2.1%N/A-15.1%$1.04B$100.64M555.5040Gap UpMLYSMineralys Therapeutics2.9279 of 5 stars$15.32-0.2%$38.00+148.0%+28.9%$998.48MN/A-4.2128Positive NewsGap UpWVEWave Life Sciences4.4021 of 5 stars$6.46+2.1%$21.17+227.7%-4.5%$995.71M$104.94M-5.82240Positive NewsGap DownPAHCPhibro Animal Health3.6143 of 5 stars$24.13+0.5%$20.00-17.1%+31.9%$978.09M$1.19B50.271,860Positive NewsAnalyst RevisionARDXArdelyx4.5083 of 5 stars$4.06+4.6%$10.39+155.9%-41.2%$971.38M$361.71M-25.3890COLLCollegium Pharmaceutical3.9539 of 5 stars$29.83-1.3%$43.80+46.8%-13.9%$958.50M$664.28M12.86210Positive NewsNTLAIntellia Therapeutics4.6181 of 5 stars$9.06+6.6%$36.90+307.3%-62.5%$938.46M$45.57M-1.67600Positive NewsGap UpHigh Trading VolumeRCUSArcus Biosciences3.0512 of 5 stars$8.70+1.6%$25.67+195.0%-43.8%$921.20M$141M-2.76500Positive News Related Companies and Tools Related Companies 89bio Competitors Aurinia Pharmaceuticals Competitors Gyre Therapeutics Competitors Mineralys Therapeutics Competitors Wave Life Sciences Competitors Phibro Animal Health Competitors Ardelyx Competitors Collegium Pharmaceutical Competitors Intellia Therapeutics Competitors Arcus Biosciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ACB) was last updated on 5/28/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredElon’s 2025 Silver Crisis (What It Means for You)Elon Musk is back in the spotlight—this time for fueling a global scramble for silver. Tesla's relentless p...GoldenCrest Metals | SponsoredBig Oil’s big pivotThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...Augusta Precious Metals | SponsoredF1 Engineering Powers This Electric Marine MotorThe future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...The Tomorrow Investor | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aurora Cannabis Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aurora Cannabis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
